1. Home
  2. KGC vs INSM Comparison

KGC vs INSM Comparison

Compare KGC & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KGC
  • INSM
  • Stock Information
  • Founded
  • KGC 1993
  • INSM 1988
  • Country
  • KGC Canada
  • INSM United States
  • Employees
  • KGC N/A
  • INSM N/A
  • Industry
  • KGC Precious Metals
  • INSM Biotechnology: Pharmaceutical Preparations
  • Sector
  • KGC Basic Materials
  • INSM Health Care
  • Exchange
  • KGC Nasdaq
  • INSM Nasdaq
  • Market Cap
  • KGC 15.8B
  • INSM 12.6B
  • IPO Year
  • KGC N/A
  • INSM 2000
  • Fundamental
  • Price
  • KGC $14.77
  • INSM $65.63
  • Analyst Decision
  • KGC Buy
  • INSM Strong Buy
  • Analyst Count
  • KGC 4
  • INSM 16
  • Target Price
  • KGC $13.50
  • INSM $95.36
  • AVG Volume (30 Days)
  • KGC 21.6M
  • INSM 2.7M
  • Earning Date
  • KGC 05-06-2025
  • INSM 05-08-2025
  • Dividend Yield
  • KGC 0.81%
  • INSM N/A
  • EPS Growth
  • KGC 177.99
  • INSM N/A
  • EPS
  • KGC 0.98
  • INSM N/A
  • Revenue
  • KGC $5,564,800,000.00
  • INSM $381,030,000.00
  • Revenue This Year
  • KGC $15.39
  • INSM $30.36
  • Revenue Next Year
  • KGC $0.39
  • INSM $115.55
  • P/E Ratio
  • KGC $15.06
  • INSM N/A
  • Revenue Growth
  • KGC 26.71
  • INSM 20.77
  • 52 Week Low
  • KGC $7.17
  • INSM $21.92
  • 52 Week High
  • KGC $15.96
  • INSM $84.91
  • Technical
  • Relative Strength Index (RSI)
  • KGC 57.12
  • INSM 36.78
  • Support Level
  • KGC $13.87
  • INSM $67.21
  • Resistance Level
  • KGC $15.96
  • INSM $73.39
  • Average True Range (ATR)
  • KGC 0.60
  • INSM 2.69
  • MACD
  • KGC -0.04
  • INSM -0.19
  • Stochastic Oscillator
  • KGC 46.65
  • INSM 19.00

About KGC Kinross Gold Corporation

Kinross Gold is a Canada-based gold producer, producing roughly 2.2 million gold equivalent ounces in 2023. The company had about a decade of gold reserves at the end of 2023. It operates mines in the Americas and West Africa after selling its low-cost Russian operations in 2022 in response to the invasion of Ukraine. The company has historically used acquisitions to fuel expansion into new regions and production growth. In 2022, Kinross purchased the Great Bear project in Canada, which, if developed, could produce an average of more than 500,000 ounces of gold per year for at least a decade.

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

Share on Social Networks: